The total diagnosed prevalent population of Complement 3 Glomerulopathy (C3G) in 2017 was 8,175 in the seven major markets. In 2017, the United States accounted for the highest diagnosed prevalent cases of C3G with 3,967 cases.
The market size of Complement 3 Glomerulopathy (C3G) in 7MM was USD 40.6 Million in 2017, which is expected to increase during the study period 2017-2030.
The key players in the Complement 3 Glomerulopathy (C3G) Market include Alexion Pharmaceuticals, Omeros, Apellis Pharma, Novartis and many others.
For more details visit: https://www.delveinsight.com/report-store/complement-3-glomerulopathy-c3g-market